发明名称 |
PREDICTING RESPONSE TO CHEMOTHERAPY USING GENE EXPRESSION MARKERS |
摘要 |
<p>The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.</p> |
申请公布号 |
EP1836629(A1) |
申请公布日期 |
2007.09.26 |
申请号 |
EP20050817266 |
申请日期 |
2005.11.04 |
申请人 |
GENOMIC HEALTH, INC.;NSABP FOUNDATION, INC. |
发明人 |
BAKER, JOFFRE, B.;BRYANT, JOHN, L.;PAIK, SOONMYUNG;SHAK, STEVEN |
分类号 |
C12Q1/68;G06F19/18;G06F19/20 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|